» Articles » PMID: 33415093

Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors

Overview
Specialty Public Health
Date 2021 Jan 8
PMID 33415093
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2). TNBC constitutes about 15-30 percent of all diagnosed invasive breast cancer cases in the United States. African-American (AA) women have high prevalence of TNBC with worse clinical outcomes than European-American (EA) women. The contributing factors underlying racial disparities have been divided into two major categories based on whether they are related to lifestyle (non-biologic) or unrelated to lifestyle (biologic). Our objective in the present review article was to understand the potential interactions by which these risk factors intersect to drive the initiation and development of the disparities resulting in the aggressive TNBC subtypes in AA women more likely than in EA women. To reach our goal, we conducted literature searches using MEDLINE/PubMed to identify relevant articles published from 2005 to 2019 addressing breast cancer disparities primarily among AA and EA women in the United States. We found that disparities in TNBC may be attributed to racial differences in biological factors, such as tumor heterogeneity, population genetics, somatic genomic mutations, and increased expression of genes in AA breast tumors which have direct link to breast cancer. In addition, a large number of non-biologic factors, including socioeconomic deprivation adversities associated with poverty, social stress, unsafe neighborhoods, lack of healthcare access and pattern of reproductive factors, can promote comorbid diseases such as obesity and diabetes which may adversely contribute to the aggression of TNBC biology in AA women. Further, the biological risk factors directly linked to TNBC in AA women may potentially interact with non-biologic factors to promote a higher prevalence of TNBC, more aggressive biology, and poor survival. The relative contributions of the biologic and non-biologic factors and their potential interactions is essential to our understanding of disproportionately high burden and poor survival rates of AA women with TNBC.

Citing Articles

Insulin resistance and cancer: molecular links and clinical perspectives.

Caturano A, Erul E, Nilo R, Nilo D, Russo V, Rinaldi L Mol Cell Biochem. 2025; .

PMID: 40089612 DOI: 10.1007/s11010-025-05245-8.


Use of medications in women with triple-negative breast cancer between 2018 and 2019 in a Brazilian public hospital: a retrospective study.

Pires M, Sobreira-da-Silva M, Araujo P, Retto M Epidemiol Serv Saude. 2025; 34:e20240180.

PMID: 40008715 PMC: 11845119. DOI: 10.1590/S2237-96222025v34e20240180.en.


Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer.

Ning B, Liu C, Kucukdagli A, Zhang J, Jing H, Zhou Z Sci Rep. 2025; 15(1):3211.

PMID: 39863788 PMC: 11762698. DOI: 10.1038/s41598-025-87315-x.


Development and validation of a nomogram to predict survival after neoadjuvant chemotherapy in elderly women with triple-negative invasive ductal breast cancer: A SEER population-based study.

Gao Y, Wang J, Wang S, Tao W, Duan R, Hao J Saudi Med J. 2025; 46(1):43-51.

PMID: 39779351 PMC: 11717112. DOI: 10.15537/smj.2025.46.1.20240341.


Dysregulated miRNA Expression and Androgen Receptor Loss in Racially Distinct Triple-Negative Breast Cancer.

Bhattarai S, Sugita B, Nunes-Souza E, Fonseca A, Chandrashekar D, Bhargava M Int J Mol Sci. 2025; 25(24).

PMID: 39769441 PMC: 11679545. DOI: 10.3390/ijms252413679.


References
1.
Brewster A, Chavez-MacGregor M, Brown P . Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014; 15(13):e625-e634. PMC: 4413447. DOI: 10.1016/S1470-2045(14)70364-X. View

2.
Sullivan H, Oprea-Ilies G, Adams A, Page A, Kim S, Wang J . Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome. Appl Immunohistochem Mol Morphol. 2013; 22(1):17-23. DOI: 10.1097/PAI.0b013e318281148e. View

3.
Chu Q, Burton G, Glass J, Smith M, Li B . Impact of race and ethnicity on outcomes for estrogen receptor-negative breast cancers: experience of an academic center with a charity hospital. J Am Coll Surg. 2010; 210(5):585-92, 592-4. DOI: 10.1016/j.jamcollsurg.2010.01.025. View

4.
Dietze E, Chavez T, Seewaldt V . Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology. Am J Pathol. 2017; 188(2):280-290. PMC: 5785535. DOI: 10.1016/j.ajpath.2017.09.018. View

5.
Martin D, Boersma B, Yi M, Reimers M, Howe T, Yfantis H . Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One. 2009; 4(2):e4531. PMC: 2638012. DOI: 10.1371/journal.pone.0004531. View